Business Wire

As Europe Prepares for Ambitious Revisions to His Regulatory Framework to Support the Green Deal’s Targets, Key Findings From the Largest European Hydrogen Mobility Initiative Highlight the Role Hydrogen Can Play

Share

A flagship project for hydrogen mobility involving nearly 50 organisations at the forefront of the sector has today published its final report detailing the key findings and learnings. The findings are released at a crucial time as the European Green Deal seeks a 90% reduction in transport related emissions by 2050.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005025/en/

Hydrogen Mobility Europe (H2ME) has completed its first phase and compiled a rich dataset since initiating in 2016: 630 hydrogen fuel cell electric vehicles have been deployed in 10 countries and 37 new hydrogen refuelling stations installed in 8 countries, achieving 14.5 million km driven and 147 tonnes of hydrogen dispensed across 68,000 refuelling events. It is the largest European deployment for hydrogen mobility to date and demonstrates the commercial potential to rollout fuel cell electric vehicles (FCEVs) and hydrogen refuelling stations (HRS) for large and small fleets.

Following the conclusion of its initial phase, H2ME recommends national and international incentives that ensure the dispensed cost of low carbon hydrogen is competitive for vehicle operators to create a level playing field with other zero emission vehicles. National, regional, and local policies that ensure continued development of the industry are also recommended. The expansion of hydrogen infrastructure as a result of H2ME, co-funded by the FCH-JU, means more FCEVs now have access to refuelling stations however the limited infrastructure prevents full operational advantages of FCEVs being realised.

Incentives such as purchase grants and tax exemptions will unlock demand from vehicle operators and bring market confidence to vehicle suppliers. Similarly, financial support applied per unit (kg) of hydrogen sold, similar to the feed in tariffs which were applied to stimulate early renewable energy uptake, will lower the price of green hydrogen at the pump. This will enable high utilisation of refuelling stations, which strengthens its business case, demonstrated by clusters of captive fleets with high mileage and heavy-duty cycles as they have significantly lower costs per kilogram of hydrogen.

The second phase of deployment will focus on developing state of the art refuelling stations, increased options for producing green hydrogen, and targeting a wider range of vehicles (from light duty to heavy duty vehicles). The lessons from phase one show that future hydrogen mobility strategies should focus more on high mileage and heavy-duty applications to provide the anchor demand for new installations. This will provide a stronger business case to the HRS operators.

Hydrogen could play a key role in enabling high mileage applications can transition to zero emission as these applications have specific operational needs such as long range and short refuelling time, that can be met by FCEVs. The overall cost of operating FCEVs in these fleets is expected to decrease rapidly in the coming years. For example, an analysis from the ZEFER project found that for high mileages applications such as taxis, and with hydrogen at €7,5/kg, FCEVs can reach parity on a total cost of ownership basis with petrol/diesel hybrids in the next 5 years.

In Denmark three Hyundai ix35 FCEVs are used by the Municipality of Copenhagen for a variety of duties as part of H2ME. They average 120 km travelled per day, with recorded distances up to 500 km in a single day, and have access to three refuelling stations within driving range. Well-to-wheel (WTW) emissions from FCEVs in Denmark are calculated at 20 gCO2e/km, compared to 34 gCO2e/km for a battery electric vehicle, 47 gCO2e/km for a battery electric SUV and 217 gCO2e/km for a diesel comparator. The use of 100% green certified electrolytic hydrogen is key to the low emissions, however FCEVs still achieve significantly lower WTW emissions than diesel or gasoline vehicles even if using hydrogen derived from fossil fuels. Similar analysis conducted in Germany and France found that FCEVs achieve significant emission savings compared to diesel or gasoline vehicles, even if using fossil-derived hydrogen, and can be even more significantly when using low carbon or green hydrogen.

The fuel cell electric vehicles deployed have completed up to 600 km of driving range on a single tank, and prove reliable with over 99% availability over their operational usage since 2016. The confirmation of technology readiness, emerging business cases and customer proposition in the project shows a path towards commercialisation.

With increasing needs for zero emissions mobility solutions to achieve environmental targets, and economics expecting to improve rapidly at scale, there is a strong case to support the commercial rollout for hydrogen mobility.

Bart Biebuyck, Executive Director at Fuel Cells and Hydrogen Joint Undertaking (FCH JU), said: “The first phase of H2ME has demonstrated that light duty hydrogen fuel cell vehicles are performant and nearing market competition with other zero emissions vehicles for high mileage applications, like taxi fleets. In addition, our flagship project was successful in supporting the onset of a European H2 infrastructure for road transport. Today, Europe has a card to play: By integrating these learnings into the heavy duty truck sector, it can capitalise on best practices of vehicles fleets and infrastructure management, making an essential contribution to a green post-Covid recovery of our economy”.

Ben Madden, Director at Element Energy, said: “We are pleased to share the results and findings of the H2ME 1 project. This project would not have been possible without the support from the FCH JU and commitment of all partners involved. Grants to support early stage commercial deployments are a critical step in the path towards commercialisation and will remain one of the key financial tools at the European level in the coming year to develop solutions for zero-emission mobility. Element Energy is very proud to have coordinated this project and to continue supporting the largest hydrogen mobility initiative in Europe.”

Dr Duncan Yellen, Managing Director at ITM Motive, said: “Participation in the H2ME project has been invaluable in providing insights into both the engineering and customer requirements for our future build programme. Thanks to the learning provided here and through other funded projects we are confident in our ability to provide the best possible designs for building the next generation of Hydrogen Refuelling Stations across the UK to match the needs of heavy duty vehicles, high use car fleets and rail.”

Nikolas Iwan, CEO of H2 Mobility, said: “20 of the more than 90 stations in Germany have been built in the H2ME project. We are proud to be partner in the largest European hydrogen mobility initiative. Collaboration is the key to a successful mobility transition, especially in the next phase were rules and regulations have to be set for the light and heavy duty transport sector.”

Anna Margrét Kornelíusdóttir, Project Manager at Icelandic New Energy Ltd, said: "The Nordic countries have long had a faith in clean hydrogen produced from their abundant renewable energy resources. Our governments have made this clear by implementing generous economic incentives and ambitious strategies.

“H2ME has demonstrated the use and reliability of hydrogen and fuel cell technology for passenger vehicles across Europe and proven the feasibility of hydrogen as a transport fuel.

“Amid rising pressure to reach decarbonisation goals, hydrogen technology represents a low carbon and low emission energy solution that can play a vital role in the next steps addressing a transition to clean energy, not only for passenger vehicles, but also heavy-duty trucks, marine vessels and even aviation”.

- Ends -

Notes to Editor

Download the full report here: https://h2me.eu/wp-content/uploads/2021/01/H2ME_Emerging-Conclusions2020.pdf

Image: https://we.tl/t-rvTibkH4Bz

Caption: 37 new hydrogen refuelling stations have been installed in 8 countries as part of the H2ME project

About H2ME

This €170 million demonstration project is co-funded with €67 million from the Fuel Cells and Hydrogen Joint Undertaking (FCH JU), a public-private partnership supporting fuel cell and hydrogen energy technologies in Europe.

Partners include project lead Element Energy, alongside AGA, Air Liquide, AREVA H2GEN, Audi, BOC, BMW, Cenex, City of Copenhagen (Kobenhavns Kommune), Communauté d’Agglomération Sarreguemines Confluence, CNR, Daimler AG, Danish Hydrogen Fuel, EIFER, GNVERT, H2 Mobility Deutschland, Honda, Hydrogen Denmark (Brintbranchen), Hydrogene de France, hySOLUTIONS, Hyundai, Icelandic New Energy Ltd, Intelligent Energy, Islenska Vetnisfelagid (H2 Iceland), Kerkhof, ITM Power, Linde AG, McPhy Energy, Michelin, Nel Hydrogen, Netherlands Ministry of Infrastructure and Water Management (Ministerie Van Infrastructuur en Waterstaat), Nissan, OMV, OPEN ENERGI, Renault, Renault Trucks, SEMITAN, Stedin, STEP, Symbio, Toyota, The University of Manchester, WaterstofNet.

This project has received funding from the Fuel Cells and Hydrogen 2 Joint Undertaking under grant agreement No 671438 & No 700350. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, Hydrogen Europe and Hydrogen Europe research.

Contact information

Declan Shepherd | PR and Social Media Officer at Cenex
Email: Declan.Shepherd@Cenex.co.uk
Website: www.h2me.eu
Twitter: @H2ME_EU

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF ® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy16.1.2021 22:15:00 CETPress release

Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 09:00:00 CETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas

Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 07:30:00 CETPress release

Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport ® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 07:00:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit

Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 21:58:00 CETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and

Snow Software Recognized as a 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management14.1.2021 20:39:00 CETPress release

Snow Software, the global leader in technology intelligence, today announced that the company was named a December 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management (SAM) Tools. Gartner defines software asset management tools as technology that “automates many of the tasks required to maintain compliance with software licenses, thereby controlling software spending.” This is the fourth Gartner Peer Insights Customers’ Choice announcement for SAM, and Snow has earned the distinction all four times. Based solely on feedback from verified customers, Gartner Peer Insights Customers’ Choice reflects reviews and ratings published within the last 12 months. Snow received 100 reviews – the most of any vendor in the market – with an overall rating of 4.6 out of 5 as of January 12, 2021. Earlier this year, Snow was recognized as a Leader in Gartner’s 2020 Magic Quadrant for Software Asset Management Tools1 and received the highest scores in three out of four use cases in

Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 19:15:00 CETPress release

Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom